Human Medicine:

SYNLAB Announce Agreement with Arquer Diagnostics for Bladder Cancer Testing

Published: 9th July 2020

SYNLAB UK & Ireland and Arquer Diagnostics, a UK-based company committed to manufacturing and marketing innovative, non-invasive tests for diagnosing and monitoring cancer, today announced that they have entered into an exclusive agreement in the UK & Ireland.

The agreement will provide access for UK-based urologists to ADXBLADDER, a urine test for people with suspected bladder cancer and those being monitored for recurrence.

ADXBLADDER, the diagnostic test at the center of the agreement between Arquer and SYNLAB, is a game-changing urine test which can rule out the presence of bladder cancer with an extremely high level of accuracy both in patients showing signs of the disease and in patients undergoing monitoring for possible recurrence.

In the UK, around 10,200 patients are diagnosed with bladder cancer each year 1, with some 5,400 people dying annually from the disease 2.

Patients who have had bladder cancer currently undergo up to four invasive cystoscopies each year to check for recurrence, meaning multiple visits to hospitals and unpleasant tests. The rigorous clinical trials run with ADXBLADDER show the non-invasive test is quicker, highly accurate and potentially, cheaper than the current standard diagnostic.

SYNLAB will provide a “collection kit” to urologists so that their patients will be able to send their urine sample directly to the SYNLAB laboratory for analysis, a simple method to provide a much needed service to bladder cancer patients

Arquer CEO, Nadia Whittley, commented:

“This agreement allows our innovative and game-changing urine test to reach the right people at the right time. ADXBLADDER gives urologists a valid tool to use in combination with cystoscopy, and with SYNLAB’s expertise and experience in laboratory analysis, we will make sure this test becomes part of their toolbox.”

SYNLAB UK & Ireland Chief Medical Officer Dr David James commented:

“SYNLAB are pleased to work with innovative companies such as Arquer diagnostics in enabling patient access to cutting edge testing which can make a positive impact on patient’s lives”.

As well as bladder cancer, Arquer’s breakthrough technology is showing positive early data in the diagnosis of prostate and endometrial cancers. The company is currently undertaking clinical evaluation of the technology in these additional tumour indications.

Click here for further information on ADXBLADDER. diagnostic testing with SYNLAB.

Source 1 & 2 – Cancer Research UK

Latest Human Medicine News
Case Studies

Published: 19th August 2021 At SYNLAB we are very proud of the services we provide with our NHS partners. Our involvement has enabled the service…

Read More (about 'Case Studies')
Stella with Staff
Hares About Town

Published: 23rd July 2021 Pathology First Sponsors Stella, The Disco Hare Pathology First is the proud sponsor of Stella the Disco Hare as part of…

Read More (about 'Hares About Town')
New Pathology Partnership to Transform Patient Care in UK Capital

Published: 1st April 2021 A partnership that will transform pathology services and help to improve the quality of patient care across South East London has…

Read More (about 'New Pathology Partnership to Transform Patient Care in UK Capital')
SYNLAB partners with Bristol Airport to provide first class COVID-19 testing service

Published: 15th December 2020 SYNLAB is teaming up with Bristol Airport to provide its customers with access to a high quality COVID-19 testing service which…

Read More (about 'SYNLAB partners with Bristol Airport to provide first class COVID-19 testing service')